Jefferies Financial Group Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price

Sangamo Therapeutics (NASDAQ:SGMO) had its target price dropped by analysts at Jefferies Financial Group from $7.00 to $3.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target points to a potential upside of 194.12% from the company’s current price.

Other analysts also recently issued reports about the company. StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Barclays increased their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Truist Financial raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Friday, December 13th. Wells Fargo & Company decreased their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Sangamo Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Sangamo Therapeutics Trading Down 56.4 %

NASDAQ:SGMO opened at $1.02 on Tuesday. The stock’s 50-day moving average is $2.14 and its 200-day moving average is $1.22. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The stock has a market cap of $212.82 million, a P/E ratio of -1.36 and a beta of 1.15.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. During the same period in the previous year, the firm posted ($0.34) EPS. As a group, equities analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds have recently added to or reduced their stakes in SGMO. Meritage Portfolio Management boosted its holdings in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 6,740 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 38,850 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock worth $956,000 after acquiring an additional 57,125 shares in the last quarter. XTX Topco Ltd grew its holdings in Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 64,981 shares during the period. Finally, Golden State Equity Partners increased its stake in Sangamo Therapeutics by 35.2% in the third quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 69,368 shares in the last quarter. 56.93% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.